Drug Price Trends for NDC 62756-0718

Average Pharmacy Cost for 62756-0718

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 62756-0718

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62756-0718 (Finasteride)

Last updated: July 27, 2025

NDC 62756-0718 refers to a formulation of finasteride, a medication primarily used for treating benign prostatic hyperplasia (BPH) and male pattern baldness. Marketed by Sun Pharmaceutical Industries under various brand names like Propecia and Proscar, this drug has seen steady demand due to its efficacy and widespread availability. This analysis examines the current market dynamics, competitive landscape, and future price trends, drawing on data from pharmaceutical reports and regulatory filings to assist business professionals in strategic decision-making.

Introduction

Finasteride, identified by NDC 62756-0718, is a 5-alpha-reductase inhibitor that has been a cornerstone in urology and dermatology since its FDA approval in 1992. This 1-mg tablet formulation targets androgen-dependent conditions, generating significant revenue in the global pharmaceutical market. As of 2024, the drug faces a maturing market influenced by generic competition, patent expirations, and evolving healthcare policies. This article provides a data-driven market analysis and price projections based on historical trends, supply chain factors, and economic forecasts, helping stakeholders anticipate opportunities and risks.

The global finasteride market reached approximately $1.2 billion in 2023, with the U.S. accounting for roughly 40% of sales [1]. Projections indicate growth at a compound annual growth rate (CAGR) of 4.5% through 2030, driven by an aging population and increasing awareness of hair loss treatments [2]. However, price volatility stems from generic influx and regulatory pressures, making accurate projections essential for investors and manufacturers.

Current Market Landscape

The market for NDC 62756-0718 operates within a competitive ecosystem dominated by generics, with Sun Pharmaceuticals holding a notable share. In the U.S., finasteride's availability as a generic since 2006 has led to price erosion, yet branded versions maintain premium pricing for specific indications. According to IQVIA data, U.S. sales of finasteride totaled around $450 million in 2023, with generics comprising 85% of volume [1].

Key players include Sun Pharmaceuticals, Merck & Co. (original developer of Propecia), and numerous generic manufacturers like Teva and Mylan. The drug's primary markets are North America and Europe, where BPH prevalence rises with demographic shifts. In 2023, the U.S. dispensed over 10 million prescriptions for finasteride, reflecting its role in outpatient care [3]. Emerging markets in Asia-Pacific, such as India and China, are expanding due to rising healthcare access, potentially increasing global demand by 15% by 2026 [2].

Market segmentation reveals strong growth in the hair loss segment, which accounts for 60% of finasteride sales, versus 40% for BPH treatments. Online pharmacies and direct-to-consumer channels have boosted accessibility, with e-commerce sales rising 20% year-over-year in 2023 [4]. However, supply chain disruptions, including raw material shortages from Asia, have intermittently affected availability, pushing prices up by 5-7% in Q2 2024.

Key Market Drivers and Challenges

Several factors propel the finasteride market forward. Demographic trends, such as the global aging population, underpin demand; the World Health Organization projects a 25% increase in individuals over 65 by 2030, correlating with higher BPH incidence [5]. Additionally, growing awareness of male pattern baldness through social media and telemedicine has expanded the consumer base, with U.S. dermatology prescriptions surging 12% in 2023 [3].

Innovation plays a role, with combination therapies—such as finasteride paired with minoxidil—gaining traction. Research from clinical trials indicates these formulations improve efficacy, potentially capturing a 10% market share by 2027 [6]. Regulatory approvals in new regions, like recent expansions in Latin America, further support growth.

Conversely, challenges include intense generic competition, which has depressed prices by 30% since 2015 [1]. Patent cliffs remain a concern; Merck's original patents expired over a decade ago, allowing low-cost alternatives to dominate. Regulatory hurdles, such as FDA scrutiny on side effects like sexual dysfunction, could impose labeling changes or market restrictions. Economic factors, including inflation and currency fluctuations, have added volatility; for instance, U.S. wholesale prices for NDC 62756-0718 rose 4% in 2023 due to supply constraints [7].

Payer dynamics also impact the market. In the U.S., insurance coverage varies, with Medicare reimbursing BPH treatments at higher rates than cosmetic uses, influencing prescribing patterns. Global trade tensions, particularly affecting API (active pharmaceutical ingredient) imports from India, pose risks to production stability.

Price Analysis and Projections

Historical pricing for NDC 62756-0718 shows a downward trend due to generics. In 2019, the average wholesale price (AWP) was $1.20 per tablet, dropping to $0.85 by 2023 amid competition [7]. Branded versions, however, command premiums—Propecia's AWP hovers at $2.50 per tablet—reflecting marketing and perceived quality.

Factors influencing prices include manufacturing costs, which have risen with energy prices and raw material shortages. In 2024, global API costs for finasteride increased by 8%, driven by supply chain issues in China [8]. Regulatory changes, such as the Inflation Reduction Act in the U.S., cap price increases for certain drugs, potentially limiting margins for NDC 62756-0718.

For projections, analysts forecast a stabilization in prices through 2027. Using data from IQVIA and Statista, we model a baseline scenario assuming 2-3% annual inflation and moderate demand growth. By 2026, the AWP for generic finasteride could range from $0.70 to $0.90 per tablet, factoring in a 5% potential upside from supply disruptions [2]. In a bullish outlook, innovation in sustained-release formulations might elevate prices by 10-15% if new patents emerge. Conversely, a bearish scenario predicts further declines to $0.60 per tablet by 2028, driven by overcapacity in generic production.

Regionally, U.S. prices may face downward pressure from PBM (pharmacy benefit manager) negotiations, while European markets could see 5% annual increases due to stricter pricing controls [9]. Long-term projections to 2030 estimate global average prices at $0.75 per tablet, with a CAGR of -1.5%, reflecting market saturation [1].

Regulatory and Patent Considerations

Regulatory oversight significantly shapes finasteride's market. The FDA classifies NDC 62756-0718 as a prescription drug, with ongoing monitoring for adverse events. Recent updates to labeling in 2022 addressed rare side effects, potentially affecting sales [10]. In Europe, the EMA enforces similar standards, while emerging markets like Brazil require local clinical data for approvals.

Patent-wise, original protections for finasteride expired in the early 2000s, but secondary patents on formulations could influence pricing. Sun Pharmaceuticals holds process patents in some regions, providing temporary barriers to entry. Businesses should monitor filings; for example, a 2023 patent application for a novel delivery system might extend exclusivity [11].

Conclusion

The market for NDC 62756-0718 demonstrates resilience amid competition, with growth opportunities in aging demographics and therapeutic innovations. Price projections indicate moderate stability, though external factors like regulations and supply chains introduce variability. Professionals must weigh these elements for informed investment and operational strategies.

Key Takeaways

• Monitor generic competition: Expect continued price pressure, with AWP potentially dropping to $0.70-$0.90 per tablet by 2026; prioritize cost efficiencies in manufacturing.
• Leverage demographic trends: Capitalize on rising demand in aging populations by expanding into Asia-Pacific markets, projected to grow 15% by 2026.
• Assess regulatory risks: Stay updated on FDA and EMA guidelines to mitigate impacts on labeling and sales.
• Incorporate innovation: Invest in combination therapies to differentiate products and potentially increase prices by 10-15%.
• Prepare for economic volatility: Factor in supply chain disruptions and inflation when projecting revenues, aiming for diversified sourcing.

FAQs

1. What factors most influence finasteride price fluctuations? Price changes for NDC 62756-0718 are primarily driven by generic competition, raw material costs, and regulatory policies, with historical declines of 30% since 2015.

2. How does the expiration of patents affect the market for this drug? Patent expirations have increased generic availability, reducing prices and market share for branded versions, but new formulation patents could offer temporary protection.

3. What are the projected growth rates for the finasteride market? The global market is expected to grow at a CAGR of 4.5% through 2030, led by demand in North America and Asia-Pacific [2].

4. How do U.S. regulations impact finasteride pricing? U.S. laws like the Inflation Reduction Act limit price increases, potentially capping AWP rises and affecting manufacturer margins.

5. What role do online sales play in finasteride distribution? Online pharmacies have increased accessibility, boosting sales by 20% in 2023, but they also heighten competition and price transparency.

References

[1] IQVIA Institute. (2024). Global Medicine Spending and Usage. Retrieved from IQVIA reports.
[2] Statista. (2023). Finasteride Market Forecast Report.
[3] Centers for Disease Control and Prevention. (2023). Prescription Drug Data.
[4] Pharmaceutical Commerce. (2024). E-commerce Trends in Pharma.
[5] World Health Organization. (2023). Ageing and Health Report.
[6] ClinicalTrials.gov. (2022). Finasteride Combination Therapy Study.
[7] FDA. (2023). National Drug Code Directory.
[8] Supply Chain Dive. (2024). API Market Analysis.
[9] European Medicines Agency. (2023). Pricing and Reimbursement Guidelines.
[10] FDA. (2022). Finasteride Labeling Update.
[11] U.S. Patent and Trademark Office. (2023). Recent Patent Filings.